-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/breast-cancer-medications_executive.pdf
September 01, 2009 - Layout 1
Background
Breast cancer is the most frequently
diagnosed noncutaneous cancer and the
second leading cause of cancer death after
lung cancer among women in the United
States. In 2008, an estimated 182,460 cases
of invasive breast cancer and 67,770 cases
of in situ breast cancer were diagnosed, and
40,480 wo…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cancer-ovarian-contraceptives_disposition-comments.pdf
June 07, 2013 - 4
Commentator &
Affiliation Section Comment Response
TEP Member 4 Executive Summary The description … Please
reword to provide a more detailed description
We have revised the sentence to be more precise … The reviewer is correct, and we have revised this
description to clarify that probabilistic analysis … This level of understanding and description should be
demanded even in an Abstract since this may be
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-262-pharmacotherapy-alcohol-disposition-comments.pdf
November 07, 2023 - Page 47: A brief description of the arms and results of the COMBINE trial (such as
that presented on … We have added a
description of COMBINE
to Section 3.1.3,
acamprosate versus
naltrexone. … - Otherwise, tables and description are adequate and descriptive
Thank you.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/ehc-research-gaps-telehealth.pdf
April 01, 2023 - AHRQ Evidence-based Practice Center Program Research Gaps Summary: Telehealth
AHRQ EVIDENCE-BASED PRACTICE CENTER (EPC)
PROGRAM RESEARCH GAPS SUMMARY:
TELEHEALTH
An AHRQ EPC Program publication summarizing evidence gaps identified across recent
EPC Program reviews for select healthcare topics addressing telehea…
-
effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/biorepositories-registries-guide-3rd-ed-addendum-white-paper.pdf
February 01, 2018 - The consent process should
involve a description of the physical risks associated with collecting the … secondary research
use of identifiable private information and identifiable specimens46:
• A general description … research that may be conducted with identifiable
private information or identifiable biospecimens;
• A description … institutions or investigators that might conduct research with such
information and biospecimens;
• A description … the identifiable private information or
identifiable biospecimens may be stored or maintained, and a description
-
effectivehealthcare.ahrq.gov/sites/default/files/medical-test-reviews-strength-evidence.ppt
June 01, 2012 - If an intermediate accuracy outcome is used, there should be a description of how the test is related
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/medical-test-reviews-strength-evidence.ppt
June 01, 2012 - If an intermediate accuracy outcome is used, there should be a description of how the test is related
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/ptsd-5-protocol-update-2023.pdf
January 01, 2023 - Treatment Description
4.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/opioids-oa-protocol.pdf
June 29, 2019 - intervention type (e.g.,
screening tool, model of care, quality improvement initiative) and brief description
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/topic-brief2-opioid-withdrawal.pdf
April 01, 2021 - Studies of treatments to support opioid tapering in patients with chronic pain
Strategy Description … 200)†
Mean 21%
(range 6-55%); 5
studies
Good: 3
studies
Poor: 3
studies
8
Strategy Description … See Appendix B for detailed description of the criteria.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/topic-brief2-opioid-withdrawal.pdf
April 01, 2021 - Studies of treatments to support opioid tapering in patients with chronic pain
Strategy Description … 200)†
Mean 21%
(range 6-55%); 5
studies
Good: 3
studies
Poor: 3
studies
8
Strategy Description … See Appendix B for detailed description of the criteria.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/AI-tools-protocol.pdf
August 15, 2023 - tool assessed
o Inputs (i.e., the instructions given to the AI, how model trained)
o Outputs (e.g., description
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/crohns-disease_research-protocol.pdf
September 01, 2010 - Background and Objectives for the Systematic Review
Background
Description of disease. … Burrill Crohn’s initial description of this disease
suggested that it could be cured with wide surgical … These studies adhered to the commonly held concepts of high quality,
including the following: a clear description
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/assessing-the-risk-of-bias-in-systematic-reviews-of-health-care-interventions-01_0.pdf
May 01, 2005 - Description of risk-of-bias categories and study design-specific assessment criteria
for randomized … The Cochrane
Handbook of Systematic Reviews offers a more detailed description of intention to treat … Description of risk-of-bias categories and study design-specific assessment criteria for randomized and … Categories of Bias
Related to Design and
Conduct of the Studyb Description … A
misleading subgroup analysis may not fit the classic description of bias or confounding, but can
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/wireless-motility-capsule-future_research.pdf
May 01, 2013 - Orienting Stakeholders
The stakeholders were provided by email a description of the project, the draft … this report.
6
Orienting Stakeholders
By emailed letters we provided the stakeholders with a description … and assessed one to three study design
suggestions for each of the final FRN, with limited textual description … List of Ongoing Studies
Title/ Identifier(s) Study Dates Description Sponsor or Principal
Investigator … Accessed at:
clinicaltrials.gov/ct2/show/NC
T01469819
B-2
Title/ Identifier(s) Study Dates Description
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/aggression_disposition-comments.pdf
July 14, 2016 - discussion of the study by Putkonen and colleagues
(2013), the text describes on p. 66 gives an excellent
description
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/schizophrenia-adult_research-protocol.pdf
September 23, 2016 - Definition and description of schizophrenia in the DSM-5.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-194-disposition-comments-inhaled-corticosteroids.pdf
March 19, 2018 - Further description
as to the domains that led to
downgrading a given outcome are
provided in the … Further description
as to the domains that led to
downgrading a given outcome
within each
intervention … Further description
as to the domains that led to
downgrading a given outcome
within each
intervention … Public reviewer
#1, Anonymous
KQ1c A description of how dosing (frequency
and cumulative dose) differs
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/allergy-seasonal_disposition-comments.pdf
July 17, 2013 - This has been corrected in the “Description of
Included Studies” for this comparison, in Table 10 (Drugs … and
Usability
It might be beneficial if the Authors reviewed the document for
consistency of the description … In the Results section, funding is reported in the narrative
description of the evidence for each comparison … Description of PICOTS was nicely done and a new term
for me, one who spends the day seeing patients.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/nppv-respiratory-failure_research-protocol.pdf
April 21, 2011 - Amendments
In the event of protocol amendments, the date of each amendment will be accompanied by a
description